Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 39 (1) , 45-60
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Antibodies against denatured HLA class II molecules detected in luminex-single antigen assayHuman Immunology, 2013
- Pros and cons for C4d as a biomarkerKidney International, 2012
- Late Antibody-Mediated Rejection After Heart Transplantation Following the Development of De Novo Donor-Specific Human Leukocyte Antigen AntibodyTransplantation, 2012
- Donor-specific antibody against denatured HLA-A1: Clinically nonsignificant?Human Immunology, 2011
- Surveillance of alloantibodies after transplantation identifies the risk of chronic rejectionKidney International, 2011
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantationThe Journal of Heart and Lung Transplantation, 2010
- Cardiovascular Mortality Among Heart Transplant Recipients With Asymptomatic Antibody-Mediated or Stable Mixed Cellular and Antibody-Mediated RejectionThe Journal of Heart and Lung Transplantation, 2009
- Using real data for a virtual crossmatchHuman Immunology, 2009
- Monitoring and treating posttransplant human leukocyte antigen antibodiesHuman Immunology, 2009
- Clinical Relevance of Preformed HLA Donor-Specific Antibodies in Kidney TransplantationAmerican Journal of Transplantation, 2008